Enlivex Therapeutics (Israel) Top Management
ENLV Stock | ILA 415.10 4.10 0.98% |
Enlivex Therapeutics employs about 71 people. The company is managed by 18 executives with a total tenure of roughly 88 years, averaging almost 4.0 years of service per executive, having 3.94 employees per reported executive. Analysis of Enlivex Therapeutics' management performance can provide insight into the company performance.
Dror Mevorach CEO Chief Executive Officer, Founder, Chief Scientific Officer |
Oren Hershkovitz CEO Chief Executive Officer |
Enlivex |
Enlivex Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1888) % which means that it has lost $0.1888 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.378) %, meaning that it generated substantial loss on money invested by shareholders. Enlivex Therapeutics' management efficiency ratios could be used to measure how well Enlivex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Enlivex Therapeutics Workforce Comparison
Enlivex Therapeutics is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 497. Enlivex Therapeutics retains roughly 71.0 in number of employees claiming about 14% of stocks in Biotechnology industry.
Enlivex Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Enlivex Therapeutics Price Series Summation is a cross summation of Enlivex Therapeutics price series and its benchmark/peer.
Enlivex Therapeutics Notable Stakeholders
An Enlivex Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enlivex Therapeutics often face trade-offs trying to please all of them. Enlivex Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enlivex Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dror Mevorach | Chief Executive Officer, Founder, Chief Scientific Officer | Profile | |
Oren Hershkovitz | Chief Executive Officer | Profile | |
Shachar Shlosberger | Chief Financial Officer | Profile | |
Abraham Havron | Independent Director | Profile | |
Gili Hart | Independent Director | Profile | |
Shai Novik | Executive Chairman of the Board | Profile | |
Odelia BenShitrit | Head of Clinical Operations | Profile | |
Sangwoo Lee | Director | Profile | |
Baruch Halpert | Director | Profile | |
Michel Habib | Director | Profile | |
Shai MBA | Ex Chairman | Profile | |
Pr MD | Founder Officer | Profile | |
Veronique AmorBaroukh | Head CMC | Profile | |
Shachar CPA | Chief Officer | Profile | |
Brian Schwartz | Director | Profile | |
Bernhard Kirschbaum | Director | Profile | |
Sigal Arad | Director HR | Profile | |
Hyun Lee | Director | Profile |
About Enlivex Therapeutics Management Performance
The success or failure of an entity such as Enlivex Therapeutics often depends on how effective the management is. Enlivex Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enlivex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enlivex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 50 people.
Please note, the presentation of Enlivex Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enlivex Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enlivex Therapeutics' management manipulating its earnings.
Enlivex Therapeutics Workforce Analysis
Traditionally, organizations such as Enlivex Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enlivex Therapeutics within its industry.Enlivex Therapeutics Manpower Efficiency
Return on Enlivex Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 203.8K | |
Net Loss Per Executive | 803.8K |
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |